1. Home
  2. JLS vs SCLXW Comparison

JLS vs SCLXW Comparison

Compare JLS & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Mortgage and Income Fund

JLS

Nuveen Mortgage and Income Fund

HOLD

Current Price

$18.26

Market Cap

103.4M

Sector

Finance

ML Signal

HOLD

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

HOLD

Current Price

$0.17

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JLS
SCLXW
Founded
2009
N/A
Country
United States
United States
Employees
N/A
31
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.4M
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JLS
SCLXW
Price
$18.26
$0.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
26.6K
4.0K
Earning Date
01-01-0001
03-07-2025
Dividend Yield
9.33%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$55,152,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.02
52 Week Low
$15.48
$0.18
52 Week High
$17.97
$0.18

Technical Indicators

Market Signals
Indicator
JLS
SCLXW
Relative Strength Index (RSI) 38.95 42.90
Support Level $18.15 $0.17
Resistance Level $18.51 $0.21
Average True Range (ATR) 0.22 0.03
MACD -0.01 -0.00
Stochastic Oscillator 25.88 47.62

Price Performance

Historical Comparison
JLS
SCLXW

About JLS Nuveen Mortgage and Income Fund

Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: